Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Clinical trials of low-dose aspirin combined with low-dose rivaroxaban

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.01.20
Views: 111

Prof Giancarlo Agnelli - University of Perugia, Perugia, Italy

Prof Giancarlo Agenelli speaks to ecancer at the International Aspirin Foundation Scientific Conference 2019 in Rome about the effectiveness of combining antiplatelet and anticoagulant strategies in high-risk patients.

He describes data from a clinical trial which evaluated the combination of low-dose aspirin and low-dose rivaroxaban.

Prof Agnelli also discusses additional measures that could reduce adverse events such as cardiovascular death and death and whether these should be incorporated into clinical guidelines.

Read more on the highlights from the 2019 International Aspirin Foundation Scientific Conference here.

Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation